NCT03026803View on ClinicalTrials.gov

A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Liver CancerHepatocellular Cancer
Interventions
DRUG

Oxaliplatin

Given IV

DRUG

Capecitabine

Given PO

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

City of Hope Medical Center

OTHER

NCT03026803 - A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer | Biotech Hunter | Biotech Hunter